About Serendex Pharmaceuticals
Serendex Pharmaceuticals is a company based in Copenhagen (Denmark) founded in 2008 was acquired by Savara Pharma in July 2016. The company has 1 employees as of December 31, 2021. Serendex Pharmaceuticals operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, Enterprise Therapeutics, Ikaria and GEn1E, among others.
- Headquarter Copenhagen, Denmark
- Employees 1 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Serenova A/S
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
1
as on Dec 31, 2021
-
Acquired by
Savara Pharma
(Jul 18, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Serendex Pharmaceuticals
Detailed funding history for Serendex Pharmaceuticals
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Serendex Pharmaceuticals
Serendex Pharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include Savara Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapeutics for rare respiratory diseases are developed by Savara Pharma.
|
Locked | Locked | Locked |
Investor details for Serendex Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Serendex Pharmaceuticals
Investment portfolio details for Serendex Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Serendex Pharmaceuticals
Detailed financials for Serendex Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Serendex Pharmaceuticals Comparisons
Peer comparison for Serendex Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Serendex Pharmaceuticals
Serendex Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, Enterprise Therapeutics, Ikaria and GEn1E, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein biologics are developed for treating rare diseases.
|
|
| Locked | Locked | Locked |
Precision medicines for lung-related diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of respiratory diseases such as cystic fibrosis
|
|
| Locked | Locked | Locked |
Therapies for respiratory-related cardiopulmonary disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of respiratory diseases
|
Detailed competitors of Serendex Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Serendex Pharmaceuticals
Complete news archive for Serendex Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Serendex Pharmaceuticals
Serendex Pharmaceuticals was founded in 2008.
Serendex Pharmaceuticals is headquartered in Copenhagen, Denmark.
As of Dec 31, 2021, the latest employee count at Serendex Pharmaceuticals is 1.
Serendex Pharmaceuticals was founded in 2008 in Copenhagen, Denmark. Focus is placed on pharmaceutical drug development for pulmonary diseases and respiratory conditions. The pipeline includes GM-CSF targeted at pulmonary alveolar proteinosis in phase 2b3, acute respiratory distress syndrome in phase 2b, and bronchiectasis in phase 2a, though the bronchiectasis trial is currently on hold. Operations center on advancing clinical trials in this sector.
Serendex Pharmaceuticals's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
Serendex Pharmaceuticals has 1 investor. Key investors include Savara Pharma.